Brief: Oncosec Announces Positive Clinical Data Of Keynote-695 Trial Assessing Tavo-Ep In Combination With Pembrolizumab

OncoSec Medical Incorporated

11/11/2022 14:28

Nov 11 (Reuters) - OncoSec Medical Inc  ONCS.O :
    * ONCOSEC ANNOUNCES POSITIVE CLINICAL DATA OF THE
KEYNOTE-695
TRIAL ASSESSING TAVO-EP IN COMBINATION WITH PEMBROLIZUMAB 
(KEYTRUDA®) IN PATIENTS WITH ADVANCED MELANOMA REFRACTORY TO
ANTI-PD-1 TREATMENT
    * ONCOSEC MEDICAL - TOP-LINE RESULTS OF PRIMARY ENDPOINT OF
KEYNOTE-695 TRIAL, ORR BY BICR BASED ON RECIST V1.1, EXPECTED TO
BE ANNOUNCED IN Q1 OF 2023
    * ONCOSEC MEDICAL INC - KEY SECONDARY ENDPOINT OF
KEYNOTE-695 WAS
MET
    * ONCOSEC MEDICAL INC - COMBINATION THERAPY WAS GENERALLY
WELL
TOLERATED WITH NO GRADE 4/5 TREATMENT-RELATED ADVERSE EVENTS
(TRAES)

Source text for Eikon:  ID:nPnc1wdga 
Further company coverage:  ONCS.O 
 ((reuters.briefs@thomsonreuters.com;))